Help governments and healthcare organisations to spend their budgets wisely

What is this track?
Meet the case of Charlie

Charlie is an eight-year-old patient suffering from acute lymphoblastic leukemia (ALL) and has undergone multiple treatments, none of which have been effective.

With limited treatment options remaining, Charlie’s estimated 10-year survival rate is only 32%. Fortunately, a groundbreaking therapy recently approved by the European Medicines Agency (EMA) offers the potential to cure Charlie.

The availability of this life-saving treatment depends on Charlie’s place of residence in Europe.

The European Union (EU) aims for universality, solidarity, access to quality healthcare, and equity for all its citizens. This means that no one should be denied access to quality care, and services should be available based on patients’ needs.

Do you wonder if:

• These EU values are upheld in Charlie’s case?
• It is fair that Charlie might not receive treatment?
• There is someone to blame if Charlie is not treated?
• It is relevant that the price of this new treatment exceeds 320,000 Euros for one child, which, by the way, could help 64 adult patients walk again after hip replacement?

Can you help?

Are you passionate about making a positive impact on healthcare decision-making? Are you interested in addressing the ethical and economic dilemmas surrounding healthcare interventions? If so, this track is for you!

Enjoy the best of Rotterdam and Oslo

This track is a partnership between the Erasmus University Rotterdam (2nd semester) and the University of Oslo (3rd semester). They excel in the fields of health economics, healthcare management and health policy. You will enjoy top academic education in two trendy, multicultural European cities. Both with thriving healthcare sectors and high-quality living standards.